Human cytomegalovirus and kidney transplantation: a clinician's update.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  American Journal of Kidney Diseases

• Publication date

  2011-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/j.ajkd.2011.04.010PMID 21684438
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.

  2013cited by this paper
• International consensus guidelines on the management of cytomegalovirus in solid organ transplantation.

  2010cited by this paper
• KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary.

  2010cited by this paper
• Cytomegalovirus risk factors in renal transplantation with modern immunosuppression

  2010cited by this paper
• De novo Thrombotic Microangiopathy Induced by Cytomegalovirus Infection Leading to Renal Allograft Loss

  2010cited by this paper
• Interleukin 2 receptor antagonists for kidney transplant recipients.

  2010cited by this paper
• Primary CMV Infections Are Common in Kidney Transplant Recipients After 6 Months Valganciclovir Prophylaxis

  2010cited by this paper
• The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High‐Risk Kidney Transplant Recipients

  2010cited by this paper
• Immunobiology of Human Cytomegalovirus: from Bench to Bedside

  2009cited by this paper
• Cytomegalovirus in Solid Organ Transplant Recipients

  2009cited by this paper
• Effect of Cytomegalovirus Viremia on Subclinical Rejection or Interstitial Fibrosis and Tubular Atrophy in Protocol Biopsy at 3 Months in Renal Allograft Recipients Managed by Preemptive Therapy or Antiviral Prophylaxis

  2009cited by this paper
• Interlaboratory Comparison of Cytomegalovirus Viral Load Assays

  2009cited by this paper
• Kaposi's sarcoma in renal transplantation: report of three cases.

  2009cited by this paper
• KDIGO clinical practice guideline for the care of kidney transplant recipients.

  2009cited by this paper
• Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences.

  2008cited by this paper
• TNF Receptor Independent Activation of the Cytomegalovirus Major Immediate Early Enhancer in Response to Transplantation

  2008cited by this paper
• Cutaneous manifestations of cytomegalovirus disease in renal transplant recipients: a case series

  2008cited by this paper
• Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation.

  2008cited by this paper
• Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial.

  2008cited by this paper
• Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.

  2008cited by this paper
• Banff '05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allograft Nephropathy (‘CAN’)

  2007cited by this paper
• Cytomegalovirus disease with Guillain–Barré syndrome in a cadaver renal allograft recipient: cause or coincidence

  2007cited by this paper
• Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients

  2007cited by this paper
• Valacyclovir Prophylaxis Versus Preemptive Valganciclovir Therapy to Prevent Cytomegalovirus Disease After Renal Transplantation

  2007cited by this paper
• Pre-emptive Treatment for Cytomegalovirus Viremia to Prevent Cytomegalovirus Disease in Solid Organ Transplant Recipients

  2006cited by this paper
• The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.

  2006cited by this paper
• 24-Week Oral Ganciclovir Prophylaxis in Kidney Recipients Is Associated with Reduced Symptomatic Cytomegalovirus Disease Compared to a 12-Week Course

  2006cited by this paper
• Whole blood real-time quantitative PCR for cytomegalovirus infection follow-up in transplant recipients.

  2006cited by this paper
• Prophylactic Versus Preemptive Oral Valganciclovir for the Management of Cytomegalovirus Infection in Adult Renal Transplant Recipients

  2006cited by this paper
• A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.

  2005cited by this paper
• Renal Ischemia/Reperfusion Injury Activates the Enhancer Domain of the Human Cytomegalovirus Major Immediate Early Promoter

  2005cited by this paper
• Valacyclovir for Cytomegalovirus Prophylaxis Reduces the Risk of Acute Renal Allograft Rejection

  2005cited by this paper
• Quantitative PCR in the diagnosis of CMV infection and in the monitoring of viral load during the antiviral treatment in renal transplant patients

  2005cited by this paper
• Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease.

  2005cited by this paper
• Meta-Analysis: The Efficacy of Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients

  2005cited by this paper
• Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival.

  2004cited by this paper
• Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients

  2004cited by this paper
• Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation

  2004cited by this paper
• New prophylactic treatment strategy for cytomegalovirus disease.

  2003cited by this paper
• Measurement of Human Cytomegalovirus Loads by Quantitative Real-Time PCR for Monitoring Clinical Intervention in Transplant Recipients

  2003cited by this paper
• Determinants of Cardiovascular Mortality After Renal Transplantation: A Role For Cytomegalovirus?

  2003cited by this paper
• Cellular immune responses in transplantation‐associated chronic viral infections

  2002cited by this paper
• Role of the Laboratory in Diagnosis and Management of Cytomegalovirus Infection in Hematopoietic Stem Cell and Solid-Organ Transplant Recipients

  2002cited by this paper
• The Impact of Cytomegalovirus Infection and Disease on Rejection Episodes in Renal Allograft Recipients

  2002cited by this paper
• Definitions of cytomegalovirus infection and disease in transplant recipients.

  2002cited by this paper
• Ganciclovir-resistant cytomegalovirus in organ transplant recipients.

  2002cited by this paper
• A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation

  2002cited by this paper
• Cytomegalovirus in renal transplantation.

  2001cited by this paper
• GUILLAIN-BARRE SYNDROME AFTER SOLID ORGAN TRANSPLANTATION

  2001cited by this paper
• A novel link between stress and human cytomegalovirus (HCMV) infection: sympathetic hyperactivity stimulates HCMV activation.

  2000cited by this paper
• Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

  2000cited by this paper
• Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis

  2000cited by this paper
• Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients

  1999cited by this paper
• Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients.

  1999cited by this paper
• Increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus disease.

  1999cited by this paper
• Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

  1999cited by this paper
• CMV infection is associated with transplant renal artery stenosis.

  1998cited by this paper
• High incidence of active cytomegalovirus infection among septic patients.

  1998cited by this paper
• Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients.

  1997cited by this paper
• Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease.

  1997cited by this paper
• Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans

  1995cited by this paper
• SYMPTOMATIC CYTOMEGALOVIRUS DISEASE IN THE CYTOMEGALOVIRUS ANTIBODY SEROPOSITIVE RENAL TRANSPLANT RECIPIENT TREATED WITH OKT31,2

  1992cited by this paper
• Comparison of culture and serology for the diagnosis of cytomegalovirus infection in kidney and liver transplant recipients.

  1990cited by this paper
• Nephrology Dialysis Transplantation the Influence of Mycophenolate Mofetil on the Incidence and Severity of Primary Cytomegalovirus Infections and Disease after Renal Transplantation

  year unknowncited by this paper

• Viral Infections in Kidney Transplant Recipients: Current Practice and Updates

  2026influential citation
• Viral infections in solid organ transplant recipients: immunological principles and intervention strategies.

  2026cites this paper
• Off-Label Use of Alemtuzumab, Belatacept, and Rapamycin in Kidney Transplantation - Long-Term Real-World Experience.

  2025cites this paper
• Proposal of Platelet Anti-aggregation in Transplant Renal Artery Stenosis

  2025cites this paper
• Adverse event profile differences between maribavir and valganciclovir: findings from the FDA adverse event reporting system

  2025cites this paper
• Differences between xenotransplantation and allogeneic kidney transplantation: the current situation and future challenges in Japan

  2025cites this paper
• CMV Viremia and Colitis in Simultaneous Pancreas-Kidney Transplantation

  2025influential citation
• Human cytomegalovirus (HCMV) trends in Sri Lanka: insights from a hospital-based seroprevalence analysis

  2025cites this paper
• Valacyclovir for the prevention of cytomegalovirus infection after kidney transplantation

  2025cites this paper
• Graft dysfunction is associated with late CMV infection after kidney transplantation

  2025cites this paper
• Unusual cause of biliary obstruction in a kidney transplant recipient with HIV

  2024cites this paper
• Cytomegalovirus Disease in Renal Allograft Recipients in the Current Immunosuppression Era

  2024cites this paper
• Current and emerging tools for simultaneous assessment of infection and rejection risk in transplantation

  2024cites this paper
• Optimizing pediatric dosage of valganciclovir prophylaxis for cytomegalovirus infection after kidney transplantation—the fourth report

  2024cites this paper
• Deciphering the pathogen heterogeneity for precise diagnosis and personalized therapeutics of infections after kidney transplantation: insights from metagenomic next-generation sequencing

  2024cites this paper
• Successful combination therapy for recurrent refractory cytomegalovirus treatment in a kidney transplant recipient

  2024cites this paper
• Inhibiting the NADase CD38 improves cytomegalovirus-specific CD8+ T cell functionality and metabolism

  2024cites this paper
• Cytomegalovirus Matching in Deceased Donor Kidney Allocation: Results From a U.S. National Simulation Model

  2024cites this paper
• Five‐year single‐center analysis of cytomegalovirus viremia in kidney transplant recipients and possible implication for novel prophylactic therapy approaches

  2024cites this paper
• Pathological Approach to Kidney Allograft Infection

  2023cites this paper
• Human cytomegalovirus‐related gastrointestinal disease after kidney transplantation: A systematic review

  2023cites this paper
• Genomic Markers Associated with Cytomegalovirus DNAemia in Kidney Transplant Recipients

  2023cites this paper
• Significant Increase in Cytomegalovirus (CMV) Infection in Solid Organ Transplants Associated With Increased Use of Thymoglobulin as Induction Therapy?

  2023cites this paper
• An unusual case of early cytomegalovirus retinitis with UTI, invasive pulmonary aspergillosis, Klebsiella Pneumonia in a renal allograft recipient

  2023cites this paper
• Investigating the relationship between the number and activity of natural killer cells with increased cytomegalovirus and CMV disease after kidney transplantation.

  2023cites this paper
• Peripheral Blood Absolute Lymphocyte Count as a Predictor of Cytomegalovirus Infection in Kidney Transplant Recipients.

  2023cites this paper
• Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV

  2022cites this paper
• Evaluation of cytomegalovirus infection/disease in IgG positive renal transplantation recipients on valaciclovir prophylaxis.

  2022cites this paper
• Population Characteristics and Clinical Outcomes from the Renal Transplant Outcome Prediction Validation Study (TOPVAS)

  2022cites this paper
• Anti‐thymocyte globulin‐mediated immunosenescent alterations of T cells in kidney transplant patients

  2022cites this paper
• Cytomegalovirus microRNAs level determination in kidney recipients post transplantation

  2022cites this paper
• Streptococcal Infection-related Glomerulonephritis in an Elderly Diabetic Patient Complicated by Hemophagocytic Syndrome and Cytomegalovirus Nephritis

  2022cites this paper
• CMV specific T cell immune response in hepatitis C negative kidney transplant recipients receiving transplant from hepatitis C viremic donors and hepatitis C aviremic donors

  2022cites this paper
• Tomography patterns of pneumonia caused by various etiologic agents during the first year after kidney transplantation

  2022cites this paper
• Clinicopathologic features of polyomavirus nephropathy: Our experience - A retrospective observational study

  2022cites this paper
• Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients

  2021cites this paper
• Concurrent cytomegalovirus enteritis and atypical hemolytic uremic syndrome with gastrointestinal tract involvement: a case report

  2021cites this paper
• A Current Review of the Etiology, Clinical Features, and Diagnosis of Urinary Tract Infection in Renal Transplant Patients

  2021cites this paper
• Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant Recipients

  2021cites this paper
• Cytomegalovirus nephritis in kidney transplant recipients: Epidemiology and outcomes of an uncommon diagnosis

  2021cites this paper
• Importance of miR-UL-148D Expression Pattern in Cytomegalovirus Infected Transplant Patients.

  2021cites this paper
• Chronic Kidney Allograft Disease: New Concepts and Opportunities

  2021cites this paper
• Tackling Chronic Kidney Transplant Rejection: Challenges and Promises

  2021cites this paper
• Assessment of Risk Factors and Outcome of Early Versus Late Cytomegalovirus Infection Infection in Living-related D+/R + Renal Allograft Recipients

  2021cites this paper
• Integral Sliding Mode Control of Immune Response for Kidney Transplantation

  2021cites this paper
• Cytomegalovirus Disease in Renal Transplanted Patients: Prevalence, Determining Factors, and Influence on Graft and Patients Outcomes

  2021cites this paper
• Cytomegalovirus in Renal Transplant Recipients from Living Donors with and without Valgancyclovir Prophylaxis and with Immunosuppression Based in Anti-thymocyte globulin or Basiliximab.

  2021cites this paper
• Effectiveness of valacyclovir prophylaxis against the occurrence of cytomegalovirus infection in kidney transplant recipients

  2020influential citation
• Donor-derived fatal hyperinfection strongyloidiasis in renal transplant recipient

  2020cites this paper
• Clinical features of BK-polyomavirus and cytomegalovirus co-infection after kidney transplantation

  2020cites this paper
• Belatacept associated - cytomegalovirus retinitis in a kidney transplant recipient: a case report and review of the literature

  2020cites this paper
• Prospective Study of Long Noncoding RNA, MGAT3-AS1, and Viremia of BK Polyomavirus and Cytomegalovirus in Living Donor Renal Transplant Recipients

  2020cites this paper
• Cytomegalovirus disease in de novo kidney-transplant recipients: comparison of everolimus-based immunosuppression without prophylaxis with mycophenolic acid-based immunosuppression with prophylaxis

  2020cites this paper
• Human Cytomegalovirus Inhibits Autophagy of Renal Tubular Epithelial Cells and Promotes Cellular Enlargement

  2020cites this paper
• Repair of an Attenuated Low-Passage Murine Cytomegalovirus Bacterial Artificial Chromosome Identifies a Novel Spliced Gene Essential for Salivary Gland Tropism

  2020cites this paper
• MCMV Dissemination from Latently-Infected Allografts Following Transplantation into Pre-Tolerized Recipients

  2020cites this paper
• Cytomegalovirus serologic matching in deceased donor kidney allocation optimizes high‐ and low‐risk (D+R− and D−R−) profiles and does not adversely affect transplant rates

  2020cites this paper
• Impact assessment and investigation of factors associated with herpesviruses viremia in the first year of renal transplantation

  2020cites this paper
• Polyomavirus and cytomegalovirus infections are risk factors for grafts loss in simultaneous pancreas and kidney transplant

  2020cites this paper
• Efficacy and Safety of Ultra-Low-Dose Valganciclovir Chemoprophylaxis for Cytomegalovirus Infection in High-Risk Kidney Transplantation Patients.

  2019cites this paper
• Early Course of the Patient With a Kidney Transplant

  2019cites this paper
• Incidence, risk factors, and outcome of BK polyomavirus infection after kidney transplantation

  2019cites this paper
• Infections after kidney transplantation. Does age matter?

  2019cites this paper
• Cytomegalovirus infection in kidney allografts: a review of literature.

  2019cites this paper
• Múltiples úlceras genitales secundarias a infección primaria por citomegalovirus en un paciente recientemente trasplantado renal

  2019cites this paper
• Human Vascular Pericytes and Cytomegalovirus Pathobiology

  2019cites this paper
• Efficacité antivirale et tolérance d’un régime d’immunosuppression à base d’everolimus et tacrolimus faible dose en transplantation rénale

  2019cites this paper
• Impacts of Interleukin-18 Polymorphisms on the Incidence of Delayed-Onset Cytomegalovirus Infection in a Cohort of Kidney Transplant Recipients

  2019cites this paper
• Importance of molecular diagnostic of viral infections in renal transplant recipients

  2019influential citation
• New treatments for cytomegalovirus in transplant patients.

  2019cites this paper
• Cytomegalovirus nephropathy in the transplant patient.

  2019cites this paper
• University of Groningen Importance of molecular diagnostic of viral infections in renal transplant recipients Rurenga-Gard, Lilli

  2019cites this paper
• Efficacy of short term valganciclovir in a standard-dose for cytomegalovirus prophylaxis in living donor kidney transplantation: a single-center report

  2019cites this paper
• A Comparison of Different Valgancyclovir Formulations in the Universal 6-Month Prophylaxis Against CMV Infection in Renal Transplant Recipients: A Randomized Single-Centre Study

  2019cites this paper
• Infections After Uterus Transplantation

  2019cites this paper
• Risk of occurrence of cytomegalovirus infection in patients undergoing organ transplantation

  2019cites this paper
• Molecular Detection and Glycoprotein B (UL55) Genotyping of Cytomegalovirus among Sudanese Renal Transplant Recipients

  2019cites this paper
• Contemporary Kidney Transplantation

  2018cites this paper
• Costo-efectividad de dos esquemas de prevención de la infección por citomegalovirus en pacientes con trasplante renal y riesgo intermedio en Colombia

  2018cites this paper
• Common viral infections in kidney transplant recipients

  2018cites this paper
• Postrenal transplant dual viral infection: A double jeopardy

  2018cites this paper
• Mesangial cells, specialized renal pericytes and cytomegalovirus infectivity: Implications for HCMV pathology in the glomerular vascular unit and post-transplant renal disease

  2018cites this paper
• Hematologic Challenges in the Critically Ill

  2018cites this paper
• Burden of cytomegalovirus reactivation post kidney transplant with antithymocyte globulin use in Thailand: A retrospective cohort study

  2018cites this paper
• Single-center analysis of infectious complications in older adults during the first year after kidney transplantation

  2018cites this paper
• The impact of cytomegalovirus in renal transplant recipients

  2018cites this paper
• Hematologic Challenges in Intensive Care Unit Patients with Solid Organ Transplants

  2018cites this paper
• Prevention of Late-Onset Cytomegalovirus Infection and Disease in Donor-Positive/Recipient-Negative Kidney Transplant Recipients Using Low-Dose Valganciclovir.

  2018cites this paper
• Cytomegalovirus Status of Kidney Transplant Recipients and Cardiovascular Risk.

  2018cites this paper
• Anemia as very late‐onset cytomegalovirus disease after kidney transplantation

  2018cites this paper
• Incidence and clinical characteristics of renal transplanted patients with infection and disease by cytomegalovirus in a transplant center

  2018cites this paper
• Cytomegalovirus-Associated Glomerulonephritis in a Kidney Transplant Recipient

  2018cites this paper
• Cytomegalovirus Disease After Liver Transplant-A Description of a Treatment-Resistant Case: A Case Report and Literature Review.

  2018cites this paper
• Infection in Kidney Transplantation

  2018influential citation
• CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.

  2017cites this paper
• Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.

  2017cites this paper
• Prevalence of cytomegalovirus disease in kidney transplant patients in an intensive care unit

  2017cites this paper
• Cytomegalovirus infection in patients with lupus nephritis: clinical and laboratory features and therapeutic considerations

  2017cites this paper
• Cytomegalovirus peritonitis after kidney transplantation diagnosed through histopathological examination

  2017cites this paper
• High human cytomegalovirus DNAemia early post‐transplantation associates with irreversible and progressive loss of renal function – a retrospective study

  2017cites this paper